Skip to main content

Research Repository

Advanced Search

Outputs (3)

Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer (2022)
Presentation / Conference Contribution
Bruce, I., Pang, L., Poole, A., & Fraser, J. (2022, November). Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer. Poster presented at Society for Endocrinology BES 2022, Harrogate

Neuroendocrine castrate resistant prostate cancer (NE-CRPC) is a lethal CRPC subtype that arises as prostate cancer cells transdifferentiate to neuroendocrine cells, evading the potent selective pressure of androgen deprivation therapies (ADT). Curre... Read More about Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer.

The expression of the chloride co-transporters NKCC1 and KCC2 is reversed in the penumbra following (2017)
Presentation / Conference Contribution
Baudel, M., Rae, M., Fraser, J., & Poole, A. (2017, April). The expression of the chloride co-transporters NKCC1 and KCC2 is reversed in the penumbra following. Presented at BNA 2017

Stroke is one of the major causes of death and disability worldwide. The harm caused by the interruption of blood flow to the brain unfolds in the subsequent hours and days, so it is critical to identify new therapeutic targets that could reduce neur... Read More about The expression of the chloride co-transporters NKCC1 and KCC2 is reversed in the penumbra following.

Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer (2016)
Presentation / Conference Contribution
Mathur, S., Mincher, D., Turnbull, A., Stevens, C., & Poole, A. Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer

Background: In spite of major advances in the diagnosis and treatment of cancer, there remains a paucity of biomarkers for early detection. Legumain is a potential cancer biomarker and a molecular target for imaging and drug targeting. Legumain is a... Read More about Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer.